Limits...
Is thrombocytosis a useful prognostic marker in renal cell carcinoma? Results of a single-center retrospective analysis.

Venkatramani V, Panda A, Kekre NS - Indian J Urol (2015 Jan-Mar)

Bottom Line: A total of 322 cases were identified.Patients with thrombocytosis also had a significantly worse stage at presentation.Patients with thrombocytosis were significantly more likely to have advanced tumors at presentation, poorer histological features, and rapid disease progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India.

ABSTRACT

Introduction: Our aim was to determine the correlation of platelet count with stage and grade of renal cell carcinoma (RCC) and to determine whether progression of disease was more likely in those with thrombocytosis.

Materials and methods: A retrospective review of patients with RCC from January 2004 to December 2011 was undertaken. Patients with no preoperative platelet count and those with multiple tumors were excluded. Disease progression was defined as appearance of local recurrence or distant metastasis on follow-up. Thrombocytosis was defined as a platelet count of >400,000/cumm. Standard tests of significance and multivariate analysis using logistic regression were performed.

Results: A total of 322 cases were identified. The median follow-up was 7 months (range, 2-84 months). The platelet count correlated significantly with higher Fuhrmann grade, as well as increasing TNM stage at diagnosis. Patients with a platelet count of >400,000/cumm (n = 35) had a significantly higher mean tumor size and worse grade at diagnosis than those with a normal platelet count (n = 287). Patients with thrombocytosis also had a significantly worse stage at presentation. Progression of disease was seen more often in patients with thrombocytosis (28.6% vs 11.9%, P = 0.07). The median time to progression was significantly faster in patients with thrombocytosis (9 vs 18 months, P = 0.018). However, on multivariate analysis TNM stage was the only significant predictor of time to progression.

Conclusion: Rising platelet count correlated significantly with advancing stage and grade of disease. Patients with thrombocytosis were significantly more likely to have advanced tumors at presentation, poorer histological features, and rapid disease progression.

No MeSH data available.


Related in: MedlinePlus

Flowchart depicting derivation of the study group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4300571&req=5

Figure 1: Flowchart depicting derivation of the study group

Mentions: Figure 1 describes the derivation of the study group after applying the exclusion criteria. A total of 649 patients with RCC were identified during the study period. There was no record of a platelet count in 308. Of the remaining 341 patients, 11 were diagnosed cases of vHL disease, and a further 8 had bilateral tumors, leaving 322 in the study group.


Is thrombocytosis a useful prognostic marker in renal cell carcinoma? Results of a single-center retrospective analysis.

Venkatramani V, Panda A, Kekre NS - Indian J Urol (2015 Jan-Mar)

Flowchart depicting derivation of the study group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4300571&req=5

Figure 1: Flowchart depicting derivation of the study group
Mentions: Figure 1 describes the derivation of the study group after applying the exclusion criteria. A total of 649 patients with RCC were identified during the study period. There was no record of a platelet count in 308. Of the remaining 341 patients, 11 were diagnosed cases of vHL disease, and a further 8 had bilateral tumors, leaving 322 in the study group.

Bottom Line: A total of 322 cases were identified.Patients with thrombocytosis also had a significantly worse stage at presentation.Patients with thrombocytosis were significantly more likely to have advanced tumors at presentation, poorer histological features, and rapid disease progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India.

ABSTRACT

Introduction: Our aim was to determine the correlation of platelet count with stage and grade of renal cell carcinoma (RCC) and to determine whether progression of disease was more likely in those with thrombocytosis.

Materials and methods: A retrospective review of patients with RCC from January 2004 to December 2011 was undertaken. Patients with no preoperative platelet count and those with multiple tumors were excluded. Disease progression was defined as appearance of local recurrence or distant metastasis on follow-up. Thrombocytosis was defined as a platelet count of >400,000/cumm. Standard tests of significance and multivariate analysis using logistic regression were performed.

Results: A total of 322 cases were identified. The median follow-up was 7 months (range, 2-84 months). The platelet count correlated significantly with higher Fuhrmann grade, as well as increasing TNM stage at diagnosis. Patients with a platelet count of >400,000/cumm (n = 35) had a significantly higher mean tumor size and worse grade at diagnosis than those with a normal platelet count (n = 287). Patients with thrombocytosis also had a significantly worse stage at presentation. Progression of disease was seen more often in patients with thrombocytosis (28.6% vs 11.9%, P = 0.07). The median time to progression was significantly faster in patients with thrombocytosis (9 vs 18 months, P = 0.018). However, on multivariate analysis TNM stage was the only significant predictor of time to progression.

Conclusion: Rising platelet count correlated significantly with advancing stage and grade of disease. Patients with thrombocytosis were significantly more likely to have advanced tumors at presentation, poorer histological features, and rapid disease progression.

No MeSH data available.


Related in: MedlinePlus